Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB

Tyck till om SwePub Sök här!

Glimelius, Ingrid, 1975- (författare): Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi

Molin, Daniel (författare): Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi

Amini, Rose-Marie (författare): Uppsala universitet,Institutionen för genetik och patologi

Gustavsson, Anita (författare): Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Oncology, Lund University

Glimelius, Bengt (författare): Karolinska Institutet,Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi

Enblad, Gunilla (författare): Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi

(creator_code:org_t)

2003-10-09
2003
Engelska.
Ingår i: European Journal of Haematology. - : Wiley. - 0902-4441 .- 1600-0609. ; 71:5, s. 327-33

Relaterad länk:: http://www3.intersci...; visa fler...; https://medicinainte...; http://dx.doi.org/10...; https://urn.kb.se/re...; https://doi.org/10.1...; https://lup.lub.lu.s...; http://kipublication...; visa färre...

Abstract Ämnesord

Stäng

The aim of this study was to evaluate treatment results for Hodgkin lymphoma (HL) patients younger than 60 yr in stage IIB, treated according to the Swedish National Care Programme. The intention was also to identify specific subgroups depending on the number of negative prognostic factors the patients have, in order to optimise and differentiate future treatment. In total, 99 patients with HL stage IIB, diagnosed between 1985 and 1994, have been analysed. There were 47 men and 52 women and the median age was 33 yr (range 17-59). Eighty-six patients presented with supradiaphragmatic disease and 13 with infradiaphragmatic. The HL specific and overall 10-yr survival was 73 and 65%, respectively. The HL-specific survival for patients in pathological stage IIB tended to be better, although not statistically significant than for clinical stage IIB, despite less chemotherapy (P = 0.1). The patients in stage IIB who were selected for laparotomy were, however, younger and with fewer negative prognostic factors. The only significant negative prognostic factor was bulky disease (P = 0.001). The following factors also tended to have a negative influence on the prognosis although not statistically significant: the International Prognostic Score, the number of involved lymph node stations, extranodal involvement and leucocyte count > 15 x 10(9)/L. In conclusion, we suggest that bulky disease should be taken into account when treating patients with stage IIB HL.

Av författaren/redakt...: Glimelius, Ingri ...; Molin, Daniel; Amini, Rose-Mari ...; Gustavsson, Anit ...; Glimelius, Bengt; Enblad, Gunilla

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.